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Introduction
Anaemia is common and important in heart failure (HF). Anaemia in HF is of multifactorial aetiology and is associated with worse symptoms and higher mortality. [1] [2] [3] [4] [5] [6] Several uncertainties remain about the clinical significance of anaemia.
For example, the Norwegian Heart Failure Registry found that anaemia did not predict all-cause mortality in community-dwelling patients with advanced HF. 7 A recent literature-based meta-analysis has shown that anaemia predicts all-cause mortality in patients with HF with both preserved and reduced ejection fraction (HF-
PEF and HF-REF)
. 4 However, this meta-analysis was based on heterogeneous inclusion criteria, with inconsistent definitions of anaemia, and as the analysis did not include patient-level data, multivariable analyses were not performed. We aimed to study the characteristics and prognostic significance of anaemia in patients with HF-PEF and with HF-REF using pooled patient-level data.
Methods
The methods for study selection and data extraction for the MAGGIC individual patient data meta-analysis have been described previously. 8 In brief, we pooled individual patient data from 31 studies that prospectively collected all-cause mortality among HF patients, and did not restrict entry criteria by EF. Data from the individual studies were re-coded into a uniform format at the Central Co-ordinating Centre at the University of Auckland, New Zealand and incorporated into one database. The protocol of the meta-analysis was approved by the University of Auckland Human Subjects Ethics Committee.
This analysis was restricted to those patients for whom haemoglobin (Hb) data at baseline were available within the main MAGGIC dataset. 8 Anaemia was defined as Hb <120 g/L in women and <130 g/L in men. 9 Patients were classified into groups according to the presence or absence of anaemia and according to ejection fraction (HF-PEF or HF-REF). As in the primary analysis of the MAGGIC dataset, preserved EF was defined as EF ≥ 50% (majority assessed by echocardiography). Reduced EF was therefore defined as EF < 50%.
Cox proportional hazard models were used to investigate the association between anaemia and 3-year all-cause mortality. Models were adjusted for age, gender, ischaemic aetiology, atrial fibrillation (AF), diabetes, hypertension, and eGFR, and were stratified by study. An interaction between gender and anaemia was assessed. 
Discussion
The main findings of our study are firstly, HF patients with anaemia were more likely to be older, have ischaemic aetiology, and have more severe signs and symptoms.
Secondly, anaemic patients were less likely to be treated with a beta-blocker and more likely to be receiving a diuretic, regardless of whether they had HF-REF or HF-PEF. Thirdly, anaemia was an independent predictor of adverse outcome for patients with HF-REF and those with HF-PEF.
As has been established in a number of prior studies, anaemia is of prognostic importance in patients with HF reported from this meta-analysis that patients with HF-PEF have lower mortality than patients with HF-REF. 8 These findings suggest that one simple marker, the Hb, is able to further stratify patients with HF-PEF (and HF-REF) into higher and lower risk subgroups. The influence of anaemia on mortality was independent of other common predictors of outcome regardless of the EF group.
Previous studies involving patients with HF with iron deficiency (with or without anaemia) have shown that treatment with iron supplements results in an improvement in quality of life and functional capacity. 5 11 However, the recent
Reduction of Events by Darbepoetin Alfa in Heart Failure (RED-HF) trial, which assessed the use of this erythropoietin analogue in patients with HF-REF and
anaemia, showed that correction of anaemia did not improve survival. 12 13 Although large-scale clinical outcome studies of the effects of erythropoietin analogues in patients with HF-PEF and anaemia are not available, a recent phase II study reported that treatment with epoetin alfa did not improve left ventricular volumes or mass, submaximal exercise capacity or quality of life. 14 These results suggest that anaemia may be a marker of poor prognosis rather than a therapeutic target for patients with HF. Reflecting these results, the recent American College of Physicians guidelines on treatment of anaemia in patients with heart disease now recommend against the use of erythropoiesis-stimulating agents in patients with anaemia and heart failure. 15 Small scale studies of the effects of intravenous iron infusions in patients with heart failure and anaemia with low ferritin levels suggest beneficial effects on exercise tolerance and quality of life. 11 However, longer term effects on clinical events remain uncertain. Such treatment is not approved for use in the United States at present 15 , although is discussed as a potential option for appropriate patients in the 2012 ESC Heart Failure Guidelines. 16 The causes of anaemia in chronic HF may be multifactorial and include haemodilution, iron loss or impaired utilisation, chronic renal failure, bone marrow suppression, inflammation and chronic disease. 2 17 18 Across a range of clinical trials and cohort studies, including the RED-HF trial 13 and the Study of Anaemia in Heart
Failure Trial (STAMINA-HeFT) 19 , community studies 20 21 , and those in the current analysis, heart failure patients with anaemia were older and had worse functional capacity than those who were not anaemic. Advanced HF is a pro-inflammatory condition 18 which, together with the common comorbidities such as renal dysfunction, will contribute to increasing frailty. 20 Thus anaemia is a common comorbidity which is prognostically important. 6 22 23 The current data suggest the possibility of higher mortality among women with nonanaemic, higher Hb levels. The prognostic significance of higher Hb levels among women with HF-PEF may be influenced by other gender-related differences in cardiovascular disease, such as proximal arterial stiffness. 23 24 Women may be more susceptible to the deleterious effects of greater pulsatile and early arterial load on diastolic function and ventricular-arterial interaction 24 , and higher Hb levels (and blood viscosity) may enhance vascular stiffness in women more than in men. 25 However women with HF-PEF and Hb > 150 g/L were not older than other women with HF-PEF, and did not have a significantly higher prevalence of hypertension, so the reasons behind the suggested increase in mortality in this group are unclear.
While a "U-shaped" relationship between Hb and mortality in patients with HF has been reported in previous studies 26 27 , this finding needs further evaluation.
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Figure 1
Hazard of all-cause mortality according to EF group and presence or absence of anaemia. Adjusted for age, gender, ischaemic aetiology, atrial fibrillation, diabetes, history of hypertension, and eGFR.
Figure 2
Hazard of all-cause mortality for haemoglobin according to EF group and gender. Adjusted for age. 
